一项评估四价与三价灭活亚单位流感疫苗在成人和老年人中免疫原性与安全性的III期随机试验,同时评估抗血凝素和病毒中和抗体应答
这项III期双盲多中心随机研究在5个欧洲国家20个中心招募1980名成人(≥18至≤60岁)和老年人(≥61岁),比较四价(QIV)与两种三价(TIV)灭活亚单位流感疫苗的免疫原性和安全性。结果显示QIV对匹配毒株免疫原性非劣于TIV,对交替谱系B毒株免疫原性优于TIV,安全性和耐受性相当。
要点
- QIV对匹配毒株的免疫应答非劣于TIV(HI几何均值比95%CI上限<1.5)。
- QIV对交替谱系B毒株的免疫应答优于TIV(HI几何均值比<1,p<0.0001)。
- QIV与TIV的局部和全身反应报告率相似。
核心结论
- QIV对匹配毒株的免疫原性非劣于TIV,对TIV中交替谱系B毒株的免疫原性优于TIV,且QIV与TIV的安全性和耐受性相当。
研究设计与样本
- III期双盲多中心随机研究,在5个欧洲国家的20个中心于2015/2016年非流行季节招募1980名受试者,随机接受QIV(n=1538)、含Victoria谱系B毒株的TIV(n=221)或含Yamagata谱系B毒株的TIV(n=221)。
主要发现
- QIV对匹配毒株的HI几何均值比95%CI上限<1.5,达到非劣效。
- QIV对交替谱系B毒株的HI几何均值比<1(p<0.0001),优于TIV。
- 反向累积分布曲线显示QIV对两种交替谱系B毒株的接种后HI和VN滴度均高于TIV。
- QIV中VN检测的血清转化率和几何均值倍数增长与HI检测对所有毒株一致。
- QIV与TIV的局部和全身反应报告率相似。
关键数值与推荐
- 非劣效界值:HI几何均值比95%CI上限<1.5。
- 优效性:HI几何均值比<1(p<0.0001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Trivalent influenza vaccines (TIVs) offer substantial protection against matching B-strains, however, protection against alternate-lineage B-strains may be enhanced by adding a second B-strain in quadrivalent influenza vaccines (QIVs). In this Phase III, double-blind, multicentre, randomised study, the immunogenicity and safety of subunit inactivated QIV versus TIV was assessed in adult (aged ≥18 to ≤60 years) and elderly (aged ≥61 years) subjects by analysing a combination of haemagglutinin inhibition (HI) and virus neutralisation (VN). METHODS: Subjects (n = 1980) were recruited off season (2015/2016) from 20 centres in five European countries and randomised to receive either QIV (n = 1538), TIV with B-strain of the Victoria lineage (n = 221) or TIV with B-strain of the Yamagata lineage (n = 221). The primary aim was to demonstrate non-inferiority of QIV to TIV for immunogenicity against matched influenza strains based on post-vaccination HI titres. Secondary aims were to show superiority of QIV to TIV for immunogenicity against alternate-lineage B-strains and to characterise the immune response by reverse cumulative distribution (RCD) curves of antibody titres and derived serological parameters for HI and VN. Reactogenicity and occurrence of adverse events were assessed post-vaccination. RESULTS: QIV elicited a non-inferior immune response for matched strains (upper limit of 95% CI for HI geometric mean ratios [GMRs] <1.5) and a superior response for alternate-lineage B-strains (HI GMRs < 1; p < 0.0001) versus TIV. RCD curves demonstrated that post-vaccination HI and VN titres were higher for QIV versus TIV for both alternate-lineage B-strains. Seroconversion rates and geometric mean fold increases of the VN assay were consistent with the HI assay for all strains in QIV. Reporting rates of local and systemic reactions were similar in both vaccine groups. CONCLUSIONS: QIV was non-inferior in immunogenicity to TIV for matched strains and superior to the alternate-lineage B-strains in TIV. Safety and tolerability profiles of QIV and TIV were comparable.
引用
- van de Witte S, Nauta J, Montomoli E, et al. A Phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects, assessing both anti-haemagglutinin and virus neutralisation antibody responses. Vaccine. 2018. PMID: 29709447. doi:10.1016/j.vaccine.2018.04.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。